In treatment-naive RA patients, lower AnxA1 levels are associated with reduced Foxp3 expression and increased IL-17 production, underscoring the importance of AnxA1 in immune regulation and anti-inflammatory processes in RA pathogenesis (19, 99). This evidence concerns the gene IL17A and rheumatoid arthritis.